comparemela.com
  1. Home
  2. Live Updates
  3. Vivani President - Breaking News

Vivani President News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

Data Published in BMC Veterinary Research shows that OKV-119 exenatide implant reduced feline weight Felines share many pathophysiologic obesity phenotypes with humans, further supporting clinical.

United statesSan franciscoAdam mendelsohnVeterinary researchDrug administrationOkava pharmaceuticalsHealth impactPharmaceuticals incVivani medical incVivani medicalVivani presidentChief executiveTerm deliverySecurities litigation reform actQuarterly report

EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use - Vivani Medical (NASDAQ:VANI)

Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research.

Adam mendelsohnVeterinary researchOkava pharmaceuticalsVivani medicalVivani president

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

NPM-115 generated significant weight loss comparable to injectable semaglutide from a single administration with expected twice-yearly dosing Vivani discloses semaglutide as the active.

United statesOzempic wegovyAdam mendelsohnVivani medical incVivani medicalBusiness wireVivani presidentChief executiveSecurities litigation reform actAnnual reportQuarterly reports

Vivani Medical Shows Preclinical Data on Weight Loss Implants

By Daniella Parra Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-115, a miniature exenatide implant for chronic weight management. The company focuses on GLP-1 implants for obesity treatment due to their potential to improve patient outcomes, which show comparable weight loss to semaglutide injections, they said. Studies in mice and rats demonstrated […]

Daniella parraAdam mendelsohnVivani medical incVivani presidentChief executiveWeight managementVivani medicalVivani presidentMedication adherence

Vivani Medical (VANI) Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic/Wegovy and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

Vivani Medical (VANI) Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic/Wegovy and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOzempic wegovyAdam mendelsohnVivani medical incVivani medicalBusiness wireVivani presidentChief executive
© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.